Cargando…

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease

INTRODUCTION: Despite the current standard of care, patients with cardiovascular disease remain at a high risk for recurrent events. Inhibition of thrombin-mediated platelet activation through protease-activated receptor-1 antagonism may provide reductions in atherosclerotic disease beyond those ach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gryka, Rebecca J., Buckley, Leo F., Anderson, Sarah M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318326/ https://www.ncbi.nlm.nih.gov/pubmed/28063023 http://dx.doi.org/10.1007/s40268-016-0158-4

Ejemplares similares

High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar
por: Zhang, Cheng, et al.
Publicado: (2012)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015)

Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation
por: Friebel, Julian, et al.
Publicado: (2021)

Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER
por: White, Harvey D., et al.
Publicado: (2014)

Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017)

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease
por: Olie, Renske H., et al.
Publicado: (2019)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015)

Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Impact of selective platelet inhibition in reducing cardiovascular risk – role of vorapaxar
por: Cheng, Judy WM
Publicado: (2016)

Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
por: Kraft, WK, et al.
Publicado: (2016)

Treatment and imaging of intracranial atherosclerotic stenosis: current perspectives and future directions
por: van den Wijngaard, Ido R., et al.
Publicado: (2016)

Vorapaxar treatment reduces mesangial expansion in streptozotocin-induced diabetic nephropathy in mice
por: Waasdorp, Maaike, et al.
Publicado: (2018)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial
por: Ungar, Leo, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

Financial Toxicity in Atherosclerotic Cardiovascular Disease in the United States: Current State and Future Directions
por: Khera, Rohan, et al.
Publicado: (2020)

Adjunctive therapies to reduce thrombotic events in patients with a history of myocardial infarction: role of vorapaxar
por: Farag, Mohamed, et al.
Publicado: (2015)

Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
por: Mszar, Reed, et al.
Publicado: (2023)

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
por: van Diepen, Sean, et al.
Publicado: (2015)

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases
por: Wu, Hongxian, et al.
Publicado: (2018)

Platelets treated with pathogen reduction technology: current status and future direction
por: Lu, Wen, et al.
Publicado: (2020)

Endovascular Treatment of Intracranial Atherosclerotic Stenosis: Current Debates and Future Prospects
por: Luo, Jichang, et al.
Publicado: (2018)

Vorapaxar stabilizes permeability of the endothelial barrier under cholesterol stimulation via the AKT/JNK and NF-κB signaling pathways
por: Pang, Jianliang, et al.
Publicado: (2019)

Alcohol and NMDA receptor: current research and future direction
por: Chandrasekar, Raman
Publicado: (2013)

Basic research in orthopedic surgery: Current trends and future directions
por: Lu, Chuanyong, et al.
Publicado: (2009)

Effect of Angiotensin II Type 1 Receptor Antagonist, Losartan on Inflammatory Factor in Atherosclerotic Rabbits
por: Xu, Yan-min, et al.
Publicado: (2013)

Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges
por: Fujii, Wataru, et al.
Publicado: (2023)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

Skin Barrier Recovery by Protease-Activated Receptor-2 Antagonist Lobaric Acid
por: Joo, Yeon Ah, et al.
Publicado: (2016)

Adenosine Receptor-Mediated Cardioprotection—Current Limitations and Future Directions
por: Lasley, Robert D.
Publicado: (2018)

Crosslink bio-adhesives for bronchoscopic lung volume reduction: current status and future direction
por: Joglekar, Mugdha M., et al.
Publicado: (2021)

Antiviral Agents against Flavivirus Protease: Prospect and Future Direction
por: Samrat, Subodh K., et al.
Publicado: (2022)

Aldosterone receptor antagonists: current perspectives and therapies
por: Guichard, Jason L, et al.
Publicado: (2013)

The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents
por: Lai, Ming-Chi, et al.
Publicado: (2019)

Pathogenesis and Management of Serrated Polyps: Current Status and Future Directions
por: Anderson, Joseph C.
Publicado: (2014)

Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets
por: Young, Summer E., et al.
Publicado: (2013)

Protease-Activated Receptor-1 Antagonist Protects Against Lung Ischemia/Reperfusion Injury
por: Chu, Shi-Jye, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_plpu0dutv45n3d148osj3qmuio